Posts tagged “Quintiles”
Quintiles, the world's largest provider of life science industry services, is growing a bit bigger but adding more expertise in healthcare analytics through the acquisition of Encore Health Resources.
From our archives: The Fred Eshelman saga includes one-person startup at PPD to Wilmington's Walk of Fame and now a $1.1B sale of Furiex
Looking back at Fred Eshelman's career: A 2009 blog post recapped a tumultuous year for Eshelman and PPD in which the company's stock was hammered and he stepped down as CEO to become executive chairman. But the year was capped with a salute. From there, Eshelman has continued to make headlines.
Quintiles, the world's largest provider of life science services such as clinical trials, and pharmaceutical firm Biogen, which has a huge manufacturing facility in RTP, have formed a "collaboration" through which the two firms will develop drug candidates in Biogen's pipeline. But neither company will discuss financial terms of the deal. There may be some hiring at Quintiles for a Biogen-focused team, but Biogen plans no layoffs.
While neither company is talking about the financials involved in their five-year partnership announced Thursday, the firms do say the agreement means the two companies will become much more than RTP neighbors.
Raleigh-based BioDelivery Sciences recently raised $60 million to help commercialize its proposed chronic pain reliever drug and hopes to win FDA approval for it in June. On Thursday, BDSI said it had chosen Durham-based Quintiles, the world's largest life science services firm, to help take the drug to market. The deal includes formation of a sales force.
A spate of Triangle life science IPOs raised more total money than those in Boston and New York in 2013, and more followed early this year. Has this open IPO window affected biotech and life science fundraising in the Triangle? Will the window remain open? One area VC suggests we may look back on 2010-2015 as a watershed time for the regional industry.
Dennis Gillings, the co-founder of Quintiles, and other investors in the world's largest life science services company, won't be getting as much as expected from an offering of stock that cashes in on a 2013 IPO.
Dennis Gillings, the co-founder of Quintiles, and other investors in the world's largest life science services company, are looking to cash in on Quntiles' IPO from last year. According to an SEC filing made early Monday, they are offering some 17.5 million shares worth $939.3 million.
An analyst quizzed Quintiles executives about the company's 2013 purchase of near-by Novella. CFO Kevin Gordon and CEO Tom Pike had plenty of good things to say, especially the financial performance. They also said Quintiles continues to look for more deals.
Investors like the overall earnings report and forecast for the coming year. Shares climb in pre-market trading. Says Quintiles CEO Tom Pike. "We are well positioned entering 2014 with the largest backlog in the industry at $9.9 billion dollars which will fuel 2014 constant currency service revenue and earnings growth.
Quintiles says more cross-industry discussions involving all stakeholders - including patients - are needed to find ways to identify and deliver health care value. Read more about the findings from Quintiles' "Value is the Target" report.
Quintiles, the world's largest life science services company is now providing patient warnings and reminders about medication through a new mobile app.
Quintiles offers a free website and now a mobile app to help people deal with personal health issues, but the company also is taking steps - including staff who monitor the site and news - in order to ensure safety and to protect itself from lawsuits. "Q" management has obviously learned the lesson of the bad guy in Magnificent Seven: No good deed goes unpunished.
SAS to tout 'Big Ideas;' Sony TV service; Quintiles' new deal; Nortel settlement; Yahoo touts ads; Twitter co-founder's startup
Our Bulldog blog wrapup of the latest technology news: SAS has big plans for the National Retail federation show; Sony plans Internet-based TV service; Quintiles strikes info deal with Georgia firm; judge OKs Nortel deal; Yahoo unveils new services; Twitter co-founder launches new photo app.
Outcome, a division of pharmaceutical services provider Quintiles isn't limited to drug studies. The company analyzed knee injuries for the NFL and found that ACL injuries are down so far this season.
India's health ministry tells that country's Supreme Court that Quintiles treated survivors of the 1984 Bhopal gas disaster as "guinea pigs" who volunteered to participate in two clinical trials for drugs. In two instances, Quintiles did not meet some standards, the government says. Quintiles denies the charges.
Insiders and private equity backers of Quintiles sold nearly $95 million worth of stock in the company last week. So why are these sales happening now? WRALTechWire Insiders get the story.
Michael Mortimer, executive vice president and chief administration officer, at Quintiles has sold shares worth more than $8 million. He's the second senior executive officer to do so in the past week.